Epilepsy in tuberous sclerosis: Phenotypes, mechanisms, and treatments

Seminars in Neurology

Volumn 35, Issue 3, 2015, Pages 269-276

  Saxena, Anurag ^a   Sampson, Julian R ^a  

^a CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

epilepsy; mTORC1; TSC1; TSC2; tuberous sclerosis

Indexed keywords

ANTICONVULSIVE AGENT; CORTICOSTEROID; FELBAMATE; LAMOTRIGINE; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; RUFINAMIDE; TOPIRAMATE; TUBERIN; TUBEROUS SCLEROSIS COMPLEX 1 PROTEIN; UNCLASSIFIED DRUG; VALPROIC ACID; VIGABATRIN; ZONISAMIDE; CALCIUM BINDING PROTEIN; TARGET OF RAPAMYCIN KINASE; TSC PROTEIN, HUMAN;

ADULT; ALEXANDER DISEASE; ARTICLE; CHILD; CORPUS CALLOSOTOMY; DISEASE ASSOCIATION; DROP ATTACK; ELECTROENCEPHALOGRAPHY; EPILEPSY; GENE MUTATION; HIPPOCAMPAL SCLEROSIS; HUMAN; HYDRAMNIOS; HYDROCEPHALUS; INFANT; INFANTILE SPASM; KETOGENIC DIET; LENNOX GASTAUT SYNDROME; MICROGYRIA; MULTICENTER STUDY (TOPIC); NEUROSURGERY; NONHUMAN; ONSET AGE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHENOTYPE; POLYDACTYLY; POLYPHARMACY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN HYPERACTIVITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASMUSSEN SYNDROME; RESECTIVE EPILEPSY SURGERY; SIGNAL TRANSDUCTION; SYMPTOMATIC EPILEPSY; TREATMENT OUTCOME; TREATMENT RESPONSE; TUBEROUS SCLEROSIS; VAGUS NERVE STIMULATION; COMPLICATION; GENETICS; MUTATION; PROCEDURES;

ANTICONVULSANTS; CALCIUM-BINDING PROTEINS; EPILEPSY; HUMANS; MUTATION; NEUROSURGICAL PROCEDURES; TOR SERINE-THREONINE KINASES; TUBEROUS SCLEROSIS;

EID: 84931263336     PISSN: 02718235     EISSN: 10989021     Source Type: Journal    
DOI: 10.1055/s-0035-1552616     Document Type: Article

References (83)

1. Crino P. B., Nathanson K. L., Henske E. P. The tuberous sclerosis complex. N Engl J Med: 2006; 355 13 1345 1356
2. European Chromosome 16 Tuberous Sclerosis Consortium Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell: 1993; 75 7 1305 1315
3. van Slegtenhorst M., de Hoogt R., Hermans C., et al. Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science: 1997; 277 5327 805 808
4. Dabora S. L., Jozwiak S., Franz D. N., et al. Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs. Am J Hum Genet: 2001; 68 1 64 80
5. Sancak O., Nellist M., Goedbloed M., et al. Mutational analysis of the TSC1 and TSC2 genes in a diagnostic setting: genotype-phenotype correlations and comparison of diagnostic DNA techniques in Tuberous Sclerosis Complex. Eur J Hum Genet: 2005; 13 6 731 741
6. Wang S., Fallah A. Optimal management of seizures associated with tuberous sclerosis complex: current and emerging options. Neuropsychiatr Dis Treat: 2014; 10 2021 2030
7. Lewis J. C., Thomas H. V., Murphy K. C., Sampson J. R. Genotype and psychological phenotype in tuberous sclerosis. J Med Genet: 2004; 41 3 203 207
8. Northrup H., Krueger D. A.; International Tuberous Sclerosis Complex Consensus Group. Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol: 2013; 49 4 243 254
9. Bissler J. J., Kingswood J. C. Renal angiomyolipomata. Kidney Int: 2004; 66 3 924 934
10. Sampson J. R., Maheshwar M. M., Aspinwall R., et al. Renal cystic disease in tuberous sclerosis: role of the polycystic kidney disease 1 gene. Am J Hum Genet: 1997; 61 4 843 851
11. Bosi G., Lintermans J. P., Pellegrino P. A., Svaluto-Moreolo G., Vliers A. The natural history of cardiac rhabdomyoma with and without tuberous sclerosis. Acta Paediatr: 1996; 85 8 928 931
12. McCormack F. X., Inoue Y., Moss J., et al. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med: 2011; 364 17 1595 1606
13. Hunt A. Tuberous sclerosis: a survey of 97 cases. III: Family aspects. Dev Med Child Neurol: 1983; 25 3 353 357
14. Webb D. W., Fryer A. E., Osborne J. P. On the incidence of fits and mental retardation in tuberous sclerosis. J Med Genet: 1991; 28 6 395 397
15. Thiele E. A. Managing epilepsy in tuberous sclerosis complex. J Child Neurol: 2004; 19 9 680 686
16. de Vries P. J., Whittemore V. H., Leclezio L., et al. Tuberous sclerosis associated neuropsychiatric disorders (TAND) and the TAND Checklist. Pediatr Neurol: 2015; 52 1 25 35
17. Leclezio L., Jansen A., Whittemore V. H., de Vries P. J. Pilot validation of the tuberous sclerosis-associated neuropsychiatric disorders (TAND) checklist. Pediatr Neurol: 2015; 52 1 16 24
18. Prabowo A. S., Anink J. J., Lammens M., et al. Fetal brain lesions in tuberous sclerosis complex: TORC1 activation and inflammation. Brain Pathol: 2013; 23 1 45 59
19. Tsai V., Parker W. E., Orlova K. A., et al. Fetal brain mTOR signaling activation in tuberous sclerosis complex. Cereb Cortex: 2014; 24 2 315 327
20. Park S. H., Pepkowitz S. H., Kerfoot C., et al. Tuberous sclerosis in a 20-week gestation fetus: immunohistochemical study. Acta Neuropathol: 1997; 94 2 180 186
21. Luat A. F., Makki M., Chugani H. T. Neuroimaging in tuberous sclerosis complex. Curr Opin Neurol: 2007; 20 2 142 150
22. Braffman B. H., Bilaniuk L. T., Naidich T. P., et al. MR imaging of tuberous sclerosis: pathogenesis of this phakomatosis, use of gadopentetate dimeglumine, and literature review. Radiology: 1992; 183 1 227 238
23. Makki M. I., Chugani D. C., Janisse J., Chugani H. T. Characteristics of abnormal diffusivity in normal-appearing white matter investigated with diffusion tensor MR imaging in tuberous sclerosis complex. AJNR Am J Neuroradiol: 2007; 28 9 1662 1667
24. Arulrajah S., Ertan G., Jordan L., et al. Magnetic resonance imaging and diffusion-weighted imaging of normal-appearing white matter in children and young adults with tuberous sclerosis complex. Neuroradiology: 2009; 51 11 781 786
25. Peng S. S., Lee W. T., Wang Y. H., Huang K. M. Cerebral diffusion tensor images in children with tuberous sclerosis: a preliminary report. Pediatr Radiol: 2004; 34 5 387 392
26. Dibble C. C., Elis W., Menon S., et al. TBC1D7 is a third subunit of the TSC1-TSC2 complex upstream of mTORC1. Mol Cell: 2012; 47 4 535 546
27. Laplante M., Sabatini D. M. Regulation of mTORC1 and its impact on gene expression at a glance. J Cell Sci: 2013; 126 Pt 8 1713 1719
28. Yecies J. L., Manning B. D. mTOR links oncogenic signaling to tumor cell metabolism. J Mol Med (Berl): 2011; 89 3 221 228
29. Parkhitko A. A., Favorova O. O., Khabibullin D. I., Anisimov V. N., Henske E. P. Kinase mTOR: regulation and role in maintenance of cellular homeostasis, tumor development, and aging. Biochemistry (Mosc): 2014; 79 2 88 101
30. Au K. S., Williams A. T., Gambello M. J., Northrup H. Molecular genetic basis of tuberous sclerosis complex: from bench to bedside. J Child Neurol: 2004; 19 9 699 709
31. Huang J., Manning B. D. The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. Biochem J: 2008; 412 2 179 190
32. Kim S. G., Buel G. R., Blenis J. Nutrient regulation of the mTOR complex 1 signaling pathway. Mol Cells: 2013; 35 6 463 473
33. Ehninger D., Han S., Shilyansky C., et al. Reversal of learning deficits in a Tsc2+/- mouse model of tuberous sclerosis. Nat Med: 2008; 14 8 843 848
34. Saxena A., Sampson J. R. Phenotypes associated with inherited and developmental somatic mutations in genes encoding mTOR pathway components. Semin Cell Dev Biol: 2014; 36 140 146
35. Tyburczy M. E., Wang J. A., Li S., et al. Sun exposure causes somatic second-hit mutations and angiofibroma development in tuberous sclerosis complex. Hum Mol Genet: 2014; 23 8 2023 2029
36. Carbonara C., Longa L., Grosso E., et al. Apparent preferential loss of heterozygosity at TSC2 over TSC1 chromosomal region in tuberous sclerosis hamartomas. Genes Chromosomes Cancer: 1996; 15 1 18 25
37. Liu J., Reeves C., Michalak Z., et al. Evidence for mTOR pathway activation in a spectrum of epilepsy-associated pathologies. Acta Neuropathol Commun: 2014; 2 71
38. Curatolo P., Verdecchia M., Bombardieri R. Tuberous sclerosis complex: a review of neurological aspects. Eur J Paediatr Neurol: 2002; 6 1 15 23
39. Curatolo P., Bombardieri R., Verdecchia M., Seri S. Intractable seizures in tuberous sclerosis complex: from molecular pathogenesis to the rationale for treatment. J Child Neurol: 2005; 20 4 318 325
40. Guzzetta F., Crisafulli A., Isaya Crinó M. Cognitive assessment of infants with West syndrome: how useful is it for diagnosis and prognosis? Dev Med Child Neurol: 1993; 35 5 379 387
41. Curatolo P., Seri S., Verdecchia M., Bombardieri R. Infantile spasms in tuberous sclerosis complex. Brain Dev: 2001; 23 7 502 507
42. Pressler R. MBC, Cooper R., Robinson R. Neonatal and Paediatric Clinical Neurophysiology. Amsterdam, The Netherlands Elsevier: 2007
43. Kinirons P., Cavalleri G. L., O'Rourke D., et al. Vigabatrin retinopathy in an Irish cohort: lack of correlation with dose. Epilepsia: 2006; 47 2 311 317
44. Bolton P. F., Park R. J., Higgins J. N., Griffiths P. D., Pickles A. Neuro-epileptic determinants of autism spectrum disorders in tuberous sclerosis complex. Brain: 2002; 125 Pt 6 1247 1255
45. Curatolo P., D'Argenzio L., Cerminara C., Bombardieri R. Management of epilepsy in tuberous sclerosis complex. Expert Rev Neurother: 2008; 8 3 457 467
46. Joinson C., O'Callaghan F. J., Osborne J. P., Martyn C., Harris T., Bolton P. F. Learning disability and epilepsy in an epidemiological sample of individuals with tuberous sclerosis complex. Psychol Med: 2003; 33 2 335 344
47. O'Callaghan F. J., Harris T., Joinson C., et al. The relation of infantile spasms, tubers, and intelligence in tuberous sclerosis complex. Arch Dis Child: 2004; 89 6 530 533
48. Hamano S., Tanaka M., Mochizuki M., Sugiyama N., Eto Y. Long-term follow-up study of West syndrome: differences of outcome among symptomatic etiologies. J Pediatr: 2003; 143 2 231 235
49. Fukushima K., Inoue Y., Fujiwara T., Yagi K. Long-term follow-up study of West syndrome associated with tuberous sclerosis. Brain Dev: 2001; 23 7 698 704
50. Lane V. W., Samples J. M. Tuberous sclerosis: case study of early seizure control and subsequent normal development. J Autism Dev Disord: 1984; 14 4 423 427
51. Jambaqué I., Chiron C., Dumas C., Mumford J., Dulac O. Mental and behavioural outcome of infantile epilepsy treated by vigabatrin in tuberous sclerosis patients. Epilepsy Res: 2000; 38 2-3 151 160
52. Aicardi J., Mumford J. P., Dumas C., Wood S.; Sabril IS Investigator and Peer Review Groups. Vigabatrin as initial therapy for infantile spasms: a European retrospective survey. Epilepsia: 1996; 37 7 638 642
53. Hancock E. C., Cross J. H. Treatment of Lennox-Gastaut syndrome. Cochrane Database Syst Rev: 2013; 2 CD003277
54. Chu-Shore C. J., Major P., Camposano S., Muzykewicz D., Thiele E. A. The natural history of epilepsy in tuberous sclerosis complex. Epilepsia: 2010; 51 7 1236 1241
55. Curatolo P. Neurological manifestations of tuberous sclerosis complex. Childs Nerv Syst: 1996; 12 9 515 521
56. Elliott R. E., Carlson C., Kalhorn S. P., et al. Refractory epilepsy in tuberous sclerosis: vagus nerve stimulation with or without subsequent resective surgery. Epilepsy Behav: 2009; 16 3 454 460
57. Vignoli A., La Briola F., Turner K., et al. Epilepsy in TSC: certain etiology does not mean certain prognosis. Epilepsia: 2013; 54 12 2134 2142
58. Moavero R., Cerminara C., Curatolo P. Epilepsy secondary to tuberous sclerosis: lessons learned and current challenges. Childs Nerv Syst: 2010; 26 11 1495 1504
59. Krueger D. A., Northrup H.; International Tuberous Sclerosis Complex Consensus Group. Tuberous sclerosis complex surveillance and management: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol: 2013; 49 4 255 265
60. Moeller J. J., Rahey S. R., Sadler R. M. Lamotrigine-valproic acid combination therapy for medically refractory epilepsy. Epilepsia: 2009; 50 3 475 479
61. Kaminski R. M., Matagne A., Patsalos P. N., Klitgaard H. Benefit of combination therapy in epilepsy: a review of the preclinical evidence with levetiracetam. Epilepsia: 2009; 50 3 387 397
62. Lazarowski A., Lubieniecki F., Camarero S., et al. Multidrug resistance proteins in tuberous sclerosis and refractory epilepsy. Pediatr Neurol: 2004; 30 2 102 106
63. Romanelli P., Najjar S., Weiner H. L., Devinsky O. Epilepsy surgery in tuberous sclerosis: multistage procedures with bilateral or multilobar foci. J Child Neurol: 2002; 17 9 689 692
64. Arya R., Tenney J. R., Horn P. S., et al. Long-term outcomes of resective epilepsy surgery after invasive presurgical evaluation in children with tuberous sclerosis complex and bilateral multiple lesions. J Neurosurg Pediatr: 2015; 15 1 26 33
65. Kawai K., Shimizu H., Yagishita A., Maehara T., Tamagawa K. Clinical outcomes after corpus callosotomy in patients with bihemispheric malformations of cortical development. J Neurosurg: 2004; 101 (1, Suppl): 7 15
66. Connolly M. B., Hendson G., Steinbok P. Tuberous sclerosis complex: a review of the management of epilepsy with emphasis on surgical aspects. Childs Nerv Syst: 2006; 22 8 896 908
67. Henry T. R. Therapeutic mechanisms of vagus nerve stimulation. Neurology: 2002; 59 6 04 S3 S14
68. Morris G. L. III, Mueller W. M. Long-term treatment with vagus nerve stimulation in patients with refractory epilepsy. The Vagus Nerve Stimulation Study Group E01-E05. Neurology: 1999; 53 8 1731 1735
69. Major P., Thiele E. A. Vagus nerve stimulation for intractable epilepsy in tuberous sclerosis complex. Epilepsy Behav: 2008; 13 2 357 360
70. Parain D., Penniello M. J., Berquen P., Delangre T., Billard C., Murphy J. V. Vagal nerve stimulation in tuberous sclerosis complex patients. Pediatr Neurol: 2001; 25 3 213 216
71. Danial N. N., Hartman A. L., Stafstrom C. E., Thio L. L. How does the ketogenic diet work? Four potential mechanisms. J Child Neurol: 2013; 28 8 1027 1033
72. McDaniel S. S., Rensing N. R., Thio L. L., Yamada K. A., Wong M. The ketogenic diet inhibits the mammalian target of rapamycin (mTOR) pathway. Epilepsia: 2011; 52 3 e7 e11
73. Levy R. G., Cooper P. N., Giri P. Ketogenic diet and other dietary treatments for epilepsy. Cochrane Database Syst Rev: 2012; 3 CD001903
74. Meikle L., Talos D. M., Onda H., et al. A mouse model of tuberous sclerosis: neuronal loss of Tsc1 causes dysplastic and ectopic neurons, reduced myelination, seizure activity, and limited survival. J Neurosci: 2007; 27 21 5546 5558
75. Feliciano D. M., Su T., Lopez J., Platel J. C., Bordey A. Single-cell Tsc1 knockout during corticogenesis generates tuber-like lesions and reduces seizure threshold in mice. J Clin Invest: 2011; 121 4 1596 1607
76. Meikle L., Pollizzi K., Egnor A., et al. Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function. J Neurosci: 2008; 28 21 5422 5432
77. Talos D. M., Kwiatkowski D. J., Cordero K., Black P. M., Jensen F. E. Cell-specific alterations of glutamate receptor expression in tuberous sclerosis complex cortical tubers. Ann Neurol: 2008; 63 4 454 465
78. Curatolo P. Mechanistic target of rapamycin (mTOR) in tuberous sclerosis complex-associated epilepsy. Pediatr Neurol: 2015; 52 3 281 289
79. Krueger D. A., Wilfong A. A., Holland-Bouley K., et al. Everolimus treatment of refractory epilepsy in tuberous sclerosis complex. Ann Neurol: 2013; 74 5 679 687
80. Orlova K. A., Parker W. E., Heuer G. G., et al. STRADalpha deficiency results in aberrant mTORC1 signaling during corticogenesis in humans and mice. J Clin Invest: 2010; 120 5 1591 1602
81. Wong M. Mechanisms of epileptogenesis in tuberous sclerosis complex and related malformations of cortical development with abnormal glioneuronal proliferation. Epilepsia: 2008; 49 1 8 21
82. Crino P. B. mTOR: A pathogenic signaling pathway in developmental brain malformations. Trends Mol Med: 2011; 17 12 734 742
83. Sarnat H., Flores-Sarnat L., Crino P., Hader W., Bello-Espinosa L. Hemimegalencephaly: foetal tauopathy with mTOR hyperactivation and neuronal lipidosis. Folia Neuropathol: 2012; 50 4 330 345